| erlotinib / Generic mfg. |
NCT00047333: Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed |
|
|
| Terminated | 2 | 80 | US | erlotinib hydrochloride, CP-358,774, erlotinib, OSI-774, laboratory biomarker analysis, pharmacological study, pharmacological studies | National Cancer Institute (NCI) | Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer | 01/06 | | | |
NCT00033462: Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer |
|
|
| Completed | 2 | 78 | US | erlotinib hydrochloride, CP-358,774, erlotinib, OSI-774, laboratory biomarker analysis | National Cancer Institute (NCI) | Adult Primary Cholangiocellular Carcinoma, Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer | 11/06 | | | |
NCT00365391: Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer |
|
|
| Completed | 2 | 27 | US | bevacizumab, anti-VEGF humanized monoclonal antibody, anti-VEGF monoclonal antibody, Avastin, rhuMAb VEGF, erlotinib hydrochloride, CP-358,774, erlotinib, OSI-774 | National Cancer Institute (NCI) | Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer | 08/08 | 06/10 | | |
|
|
NCT00532441: Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas |
|
|
| Terminated | 2 | 25 | US | Erlotinib, Docetaxel | Gabi Chiorean, MD, Sanofi, OSI Pharmaceuticals | Hepatocellular Carcinoma | 08/10 | 08/10 | | |
NCT00287222: Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma |
|
|
| Completed | 2 | 21 | US | Bevacizumab, Avastin, Erlotinib, Tarceva | University of Arkansas, Genentech, Inc. | Hepatocellular Carcinoma | 09/10 | 09/10 | | |
NCT00605722: A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer. |
|
|
| Completed | 2 | 51 | RoW | bevacizumab (Avastin), erlotinib (Tarceva) | Hoffmann-La Roche | Liver Cancer | 09/10 | 09/10 | | |
NCT00242502: Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery |
|
|
| Completed | 2 | 62 | US | Bevacizumab (Avastin), Anti-VEGF monoclonal antibody, rhuMAb-VEGF, Erlotinib, Erlotinib Hydrochloride, OSI-774, Tarceva | M.D. Anderson Cancer Center, Genentech, Inc. | Hepatocellular Carcinoma, Liver Cancer | 10/11 | 10/11 | | |
|
NCT00832637: Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers |
|
|
| Terminated | 2 | 33 | US | Cisplatin, Platinol®, Erlotinib, Tarceva®, Gemcitabine, Gemzar® | New Mexico Cancer Care Alliance | Hepatocellular Carcinoma, Cholangiocellular Carcinoma, Cholangiocarcinoma of the Extrahepatic Bile Duct, Bile Duct Cancer, Periampullary Adenocarcinoma, Gallbladder Cancer, Extrahepatic Bile Duct Cancer | 06/13 | 03/17 | | |
NCT00881751: Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer |
|
|
| Completed | 2 | 95 | US | bevacizumab, erlotinib hydrochloride, sorafenib tosylate | Medical University of South Carolina | Liver Cancer | 05/16 | 02/17 | | |
|
NCT00791544: Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma |
|
|
| Terminated | 1/2 | 13 | Europe | AVE1642, sorafenib, Nevaxar, erlotinib, Tarceva | Sanofi | Liver Carcinoma | 11/09 | 11/09 | | |
NCT00293436: Celecoxib and Erlotinib in Treating Patients With Liver Cancer |
|
|
| Withdrawn | 1/2 | 0 | US | celecoxib, erlotinib hydrochloride, adjuvant therapy | University of California, San Francisco, National Cancer Institute (NCI) | Liver Cancer | | | | |
